Showing 581 - 600 results of 643 for search '"Stockholm"', query time: 0.06s Refine Results
  1. 581
  2. 582

    Cardiovascular health in breast cancer patients: insight on BRCA1/2 mutations impact by Panagiotis Mallios, Mehdi Dehghan Manshadi, Laila Hubbert, Tajeri Aydin, Claudia Maes, Johanna Rantala, Annelie Liljegren, Narsis A. Kiani, Elham Hedayati

    Published 2025-01-01
    “…Methods This descriptive retrospective cohort study analyzed BC patients from 1995 to 2020 in Stockholm-Gotland, Sweden. Data from regional and national registries provided insights into CVRFs, pre-existing CVDs, demographics, and cancer treatments. …”
    Get full text
    Article
  3. 583
  4. 584
  5. 585

    The Question of Diplomatic Mission of Czechoslovakia in Lithuania in 1921-1939 by Dalia Bukelevičiūtė

    Published 2004-06-01
    “…The embassy was opened only formally: the ambassador extraordinary resided in Stockholm (till 1936), whereas a consul in Kaunas got the charge d'affaires title. …”
    Get full text
    Article
  6. 586

    Shaping Treatment Expectation to Optimize Efficacy of Interleukin 17A Antagonist Secukinumab in Psoriasis Patients by Hölsken S, Krefting F, Mühlhaus S, Bese D, Schedlowski M, Sondermann W

    Published 2025-01-01
    “…Stefanie Hölsken,1 Frederik Krefting,2 Senta Mühlhaus,2 Daniela Bese,2 Manfred Schedlowski,1,3 Wiebke Sondermann2 1Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; 2Department of Dermatology, Venereology and Allergology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; 3Department of Clinical Neuroscience, Osher Center for Integrative Medicine, Karolinska Institutet, Stockholm, 171 77, SwedenCorrespondence: Stefanie Hölsken, Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, Hufelandstraße 55, Essen, 45147, Germany, Email Stefanie.Hoelsken@uk-essen.dePurpose: Patients’ treatment expectations significantly influence the effectiveness of medical and pharmacological treatments. …”
    Get full text
    Article
  7. 587
  8. 588
  9. 589
  10. 590
  11. 591
  12. 592
  13. 593
  14. 594
  15. 595
  16. 596
  17. 597
  18. 598

    Overall Survival of Patients with Metastatic Renal Cell Carcinoma Following the Introduction of Targeted and Immunotherapies: A Norwegian Retrospective, Real-World Registry Data St... by Puco K, Notland CS, Szulkin R, Jonasson C, Beisland C, Johannesen TB, Solli O, Oldenburg J, Heinrich D

    Published 2025-01-01
    “…Katarina Puco,1 Cathrine S Notland,2 Robert Szulkin,3,4 Christian Jonasson,5 Christian Beisland,6,7 Tom B Johannesen,8 Oddvar Solli,9 Jan Oldenburg,10,11 Daniel Heinrich12 1Department of Oncology, Hematology and Palliative Care, Lovisenberg Diaconal Hospital, Oslo, Norway; 2Department of Medical Affairs, Pfizer AS, Oslo, Norway; 3SDS Life Science, Stockholm, Sweden; 4Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Solna, Sweden; 5Department of Public Health and Nursing, Faculty of Medicine and Health Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; 6Department of Urology, Haukeland University Hospital, Bergen, Norway; 7Department of Clinical Medicine, University of Bergen, Bergen, Norway; 8Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway; 9Health and Value, Pfizer AS, Oslo, Norway; 10Department of Oncology, Akershus University Hospital HF, Lørenskog, Norway; 11Faculty of Medicine, University of Oslo, Oslo, Norway; 12Department of Radiotherapy and Oncology, Innlandet Hospital Trust HF, Division Gjøvik/Lillehammer, NorwayCorrespondence: Katarina Puco, Department of Oncology, Hematology and Palliative Care, Lovisenberg Diaconal Hospital, Oslo, Norway, Tel +47  416 86 298, Email katarina.puco@lds.noPurpose: In Norway, 5-year survival rates of patients with renal cell carcinoma (RCC) are increasing. …”
    Get full text
    Article
  19. 599
  20. 600